Tag: Chris Boshoff
Pfizer’s immunotherapy ELREXFIO approved in EU for multiple myeloma
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. ... Read More
Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More
IBRANCE fails to meet primary endpoint in early breast cancer trial
Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage ... Read More
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover ... Read More
Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab
Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination ... Read More